van Eden Willem
University of Utrecht, Institute of Infectious Diseases and Immunology, Yalelaan 1, 3584CL Utrecht, The Netherlands.
Curr Opin Investig Drugs. 2008 May;9(5):523-33.
CBio Ltd, under license from the University of Queensland, is developing a recombinant form of chaperonin 10, known as XToll, for the potential anti-inflammatory treatment of rheumatoid arthritis, psoriasis and multiple sclerosis. All three indications have been evaluated in phase IIa clinical trials. By May 2005, a phase IIa trial for Crohn's disease had been terminated due to slow recruitment. The company has not disclosed plans for future development for this indication.
昆士兰大学授权的CBio有限公司正在研发一种伴侣蛋白10的重组形式，称为XToll，用于类风湿性关节炎、牛皮癣和多发性硬化症的潜在抗炎治疗。所有这三种适应症均已在IIa期临床试验中进行了评估。到2005年5月，一项针对克罗恩病的IIa期试验因招募缓慢而终止。该公司尚未披露该适应症未来的开发计划。
